• Vaccine Ontology ID: VO_0004139
• Type: Live, attenuated vaccine
• Antigen: The antigens used in the production of this vaccine are: Recombinant frag C, S. Typhi flagella, S.Typhi LPS, S.Typhi lysate, whole-cell heat phenolyzed S. Typhi, PHA, and BSA (Pasetti et al., 1999).
• Frag C gene engineering:
  • Type: Other
  • Description: Frag C encoding tetanous toxin was introduced into CVD 915 (Pasetti et al., 1999).
  • Detailed Gene Information: Click Here.
• Preparation: CVD 915 was manipulated with electroporation with plasmids pTETner15 and pcDNAtetc. guaBA was deleted from S. Typhi strain 915, which interrupts the biosynthesis of guanine nucleatides (Pasetti et al., 1999).
• Virulence: High titers of IgG1, IgG2a, and IgG2b were observed against Frag C, elicited by the CVD 915. High titers of serum IgG antibody against S. Typhi flagella and LPS were observed in mice vaccinated with the CVS 915. Titers increased significantly following the booster dose.

Mouse Response

• Host Strain: BALB/c
• Vaccination Protocol: BALB/c mice were injected immunized intranasally with 2x10^9 CFU of CVD 915 in a 30 microliter volume. Mice were boosted in the same manner 35 days later (Pasetti et al., 1999).
• Immune Response: Immunization with CVD 915 elicited sensitized lymphoid cells that proliferated in the presence of Frag C. A strong immune response was observed (Pasetti et al., 1999).
• Challenge Protocol: BALM/c mice were challenged with 50-100 lethal doses of tetanus toxin (Pasetti et al., 1999) .